Enhancement of osteosarcoma cell sensitivity to cisplatin using paclitaxel in the presence of hyperthermia

References

• Bacci G, Balladelli A, Palmerini E, Alberghini M, Pollastri P, Galletti S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities in preadolescentpatients: The Rizzoli Institute experience. J Pediatr Hematol Oncol 2008;30:908–912
   PubMedGoogle Scholar
• Bacci G, Rocca M, Salone M, Balladelli A, Ferrari S, Palmerini E, et al. High grade osteosarcoma of the extremities with lung metastases at presentation: Treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. J Surg Oncol 2008;98:415–20
   PubMed Web of Science ®Google Scholar
• Franke M, Hardes J, Helmke K, Jundt G, Jurgens H, Kempf-Bielack B, et al. Solitary skeletal osteosarcoma recurrence. Findings from the Cooperative Osteosarcoma Study Group. Pediatr Blood Cancer 2011;56:771–6
   PubMedGoogle Scholar
• Andreou D, Bielack SS, Carrle D, Kevric M, Kotz R, Winkelmann W, et al. The influence of tumor- and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. Ann Oncol 2011;22:1228–35
   PubMedGoogle Scholar
• Routt SM, Zhu J, Zaleski JM, Dynlacht JR. Potentiation of metalloenediyne cytotoxicity by hyperthermia. Int J Hyperthermia 2011;27:435–44
   PubMed Web of Science ®Google Scholar
• Streckfus CF, Brown RE, Bull JM. Proteomics, morphoproteomics, saliva and breast cancer: An emerging approach to guide the delivery of individualised thermal therapy, thermochemotherapy and monitor therapy response. Int J Hyperthermia 2010;26:649–61
   PubMed Web of Science ®Google Scholar
• Trieb K, Blahovec H, Kubista B. Effects of hyperthermia on heat shock protein expression, alkaline phosphatase activity and proliferation in human osteosarcoma cells. Cell Biochem Funct 2007;25:669–72
   PubMedGoogle Scholar
• Fan QY, Ma BA, Zhou Y, Zhang MH, Hao XB, et al. Bone tumors of the extremities or pelvis treated by microwave-induced hyperthermia. Clin Orthop Relat Res 2003;406:165–75
   PubMed Web of Science ®Google Scholar
• Shido Y, Nishida Y, Suzuki Y, Kobayashi T, Ishiguro N, et al. Targeted hyperthermia using magnetite cationic liposomes and an alternating magnetic field in a mouse osteosarcoma model. J Bone Joint Surg Br 2010;92:580–5
   PubMedGoogle Scholar
• Shen H, Li XD, Wu CP, Yin YM, Wang RS, Shu YQ, et al. The regimen of gemcitabine and cisplatin combined with radio frequency hyperthermia for advanced non-small cell lung cancer: A phase II study. Int J Hyperthermia 2011;27:27–32
   PubMed Web of Science ®Google Scholar
• Muenyi CS, States VA, Masters JH, Fan TW, Helm CW, States JC, et al. Sodium arsenite and hyperthermia modulate cisplatin-DNA damage responses and enhance platinum accumulation in murine metastatic ovarian cancer xenograft after hyperthermic intraperitoneal chemotherapy (HIPEC). J Ovarian Res 2011;22:4–9
   Google Scholar
• Babincov M, Altanerov V, Altaner C, Bergemann C, Babinec P, et al. In vitro analysis of cisplatin functionalized magnetic nanoparticles in combined cancer chemotherapy and electromagnetic hyperthermia. IEEE Trans Nanobioscience 2008;7:15–19
   PubMed Web of Science ®Google Scholar
• Liu B, Yang M, Li X, Qian X, Shen Z, Ding Y, et al. Enhanced efficiency of thermally targeted taxanes delivery in a human xenograft model of gastric cancer. J Pharm Sci 2008;97:3170–81
   PubMed Web of Science ®Google Scholar
• Michalakis J, Georgatos SD, de Bree E, Polioudaki H, Romanos J, Georgoulias V, et al. Short-term exposure of cancer cells to micromolar doses of paclitaxel, with or without hyperthermia, induces long-term inhibition of cell proliferation and cell death in vitro. Ann Surg Oncol 2007;14:1220–8
   PubMed Web of Science ®Google Scholar
• Zoul Z, Filip S, Melichar B, Dvorak J, Odrazka K, Petera J, et al. Weekly paclitaxel combined with local hyperthermia in the therapy of breast cancer locally recurrent after mastectomy – A pilot experience. Onkologie 2004;27:385–8
   PubMedGoogle Scholar
• Mohamed F, Marchettini P, Stuart OA, Urano M, Sugarbaker PH, et al. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol 2003;10:463–8
   PubMed Web of Science ®Google Scholar
• de Bree E, Theodoropoulos PA, Rosing H, Michalakis J, Romanos J, Beijnen JH, et al. Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: From laboratory bench to bedside. Cancer Treat Rev 2006;32:471–82
   PubMed Web of Science ®Google Scholar
• de Bree E, Rosing H, Michalakis J, Romanos J, Relakis K, Theodoropoulos PA, et al. Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination. Eur J Surg Oncol 2006;32:666–70
   PubMedGoogle Scholar
• Low WK, Kong SW, Tan MG. Ototoxicity from combined cisplatin and radiation treatment: An in vitro study. Int J Otolaryngol 2010;2010:523976
   PubMedGoogle Scholar
• Ulukaya E, Acilan C, Yilmaz M, Yilmaztepe-Oral A, Ari F, Zik B, et al. sFas levels increase in response to cisplatin-based chemotherapy in lung cancer patients. Cell Biochem Funct 2010;28:565–70
   PubMed Web of Science ®Google Scholar
• Huang CR, Jin ZX, Dong L, Tong XP, Yue S, Kawanami T, et al. Cisplatin augments FAS-mediated apoptosis through lipid rafts. Anticancer Res 2010;30:2065–71
   PubMedGoogle Scholar
• Drago-Ferrante R, Santulli A, Di Fiore R, Giuliano M, Calvaruso G, Tesoriere G, et al. Low doses of paclitaxel potently induce apoptosis in human retinoblastoma Y79 cells by up-regulating E2F1. Int J Oncol 2008;33:677–87
   Google Scholar
• Pires NM, Eefting D, de Vries MR, Quax PH, Jukema JW, et al. Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries. Heart 2007;93:922–7
   PubMedGoogle Scholar
• Stumm S, Meyer A, Lindner M, Bastert G, Wallwiener D, Guckel B, et al. Paclitaxel treatment of breast cancer cell lines modulates Fas/Fas ligand expression and induces apoptosis which can be inhibited through the CD40 receptor. Oncology 2004;66:101–11
   PubMedGoogle Scholar
• Huisman C, Ferreira CG, Bröker LE, Rodriguez JA, Smit EF, Postmus PE, et al. Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460. Clin Cancer Res 2002;8:596–606
   PubMed Web of Science ®Google Scholar
• Wang X, Gao XH, Li X, Hong Y, Qi R, Chen HD, et al. Local hyperthermia induces apoptosis of keratinocytes in both normal skin and condyloma acuminata via different pathways. Apoptosis 2009;14:721–8
   PubMed Web of Science ®Google Scholar
• Yu DY, Matsuya Y, Zhao QL, Ahmed K, Wei ZL, Nemoto H, et al. Enhancement of hyperthermia-induced apoptosis by a new synthesized class of furan-fused tetracyclic compounds. Apoptosis 2007;12:1523–32
   PubMedGoogle Scholar
• O’Reilly LA, Tai L, Lee L, Kruse EA, Grabow S, Fairlie WD, et al. embrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 2009;461(7264):659–63
   PubMedGoogle Scholar
• Lee H, Kim S, Choi BH, Park MT, Lee J, Jeong SY, et al. Hyperthermia improves therapeutic efficacy of doxorubicin carried by mesoporous silica nanocontainers in human lung cancer cells. Int J Hyperthermia 2011;27:698–707
   PubMed Web of Science ®Google Scholar
• Shen H, Li XD, Wu CP, Yin YM, Wang RS, Shu YQ. The regimen of gemcitabine and cisplatin combined with radio frequency hyperthermia for advanced non-small cell lung cancer: A phase II study. Int J Hyperthermia 2011;27:27–32
   PubMed Web of Science ®Google Scholar